(USD) | Mar 2024 | Q/Q |
---|---|---|
Revenue | 64.5MM | -9% |
Gross Profit | 22.1MM | -12% |
Cost Of Revenue | 42.4MM | -6% |
Operating Income | -21.8MM | -86% |
Operating Expenses | 43.9MM | -75% |
Net Income | -13.5MM | -89% |
R&D | 11.4MM | -4% |
G&A | 21.5MM | -32% |
Marketing | 9MM | -14% |
Amortization | 2MM | +2% |
Interest Expense | - | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Fulgent Genetics ( NASDAQ:FLGT ) First Quarter 2024 Results Key Financial Results Revenue: US$64.5m (down 2.5% from 1Q...
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2024 Earnings Call Transcript May 3, 2024 Fulgent Genetics, Inc. beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.33. Fulgent Genetics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to […]
Despite a slight revenue dip, Fulgent Genetics showcases strategic advancements and robust future prospects in precision diagnostics and pharmaceutical development.
Q1 2024 Fulgent Genetics Inc Earnings Call
Despite Revenue Near Estimates, Losses Exceed Expectations
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of 96.97% and 1.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
EL MONTE, Calif., May 03, 2024--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2024.
EL MONTE, Calif., April 11, 2024--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2024 financial results before the market opens on Friday, May 3, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions.
Fulgent Genetics, Inc. ( NASDAQ:FLGT ) shareholders might be concerned after seeing the share price drop 25% in the...
Key Insights The projected fair value for Fulgent Genetics is US$33.29 based on 2 Stage Free Cash Flow to Equity...